objective To assess the proportion and sales of unapproved Fixed Dose Combinations (FDCs) of anti-tubercular, antimalarial and antiretroviral medicines available on the Indian market. results Of 110 available first-to fourth-line anti-tubercular FDCs, only 32 were approved. Of 20 antimalarial FDCs available, eight were approved. However, almost 95% of available antiretroviral FDCs and branded products were approved. The sales volume of all anti-tubercular drugs was 730 million units of which 71% were unapproved, amounting to 14.30 billion rupees in sales value (58%). Almost half of the sales value and volume of antimalarials was generated by unapproved products. About 1% of sales volume of antiretroviral FDCs came from unapproved formulations, accounting for 5% of sales value.
Introduction
A Fixed Dose Combination (FDC) or combination product is a formulation combining more than one active pharmaceutical ingredient (API) in a fixed ratio of doses formulated into a single dosage form [1, 2] . Such FDCs are acceptable if they provide a clear clinical advantage over a single drug therapy without compromising safety [1, 3, 4] . The advantages offered by FDCs can be categorised into three types: clinical, patient-centred and manufacturing.
FDCs offer clinical advantage by potentiating the therapeutic efficacy, increasing bioavailability through pharmacokinetic interactions and reducing the risk of development of pathogen resistance. Further they increase the patient adherence by reducing the pill burden [5] . If there is a significant market demand, then FDCs would be cost-effective for a pharmaceutical company to manufacture, distribute and stock vis-a-vis single drug product. Further they provide a lucrative way of extending priority rights and patents for pharmaceutical companies. However, FDCs are not devoid of limitations and in some cases disadvantages. The use of FDCs would be unadvisable if a patient needs dose adjustment or a combination product employs two drugs acting on the same enzyme system, which are unlikely to result in efficacy gains. Drugs included in FDCs may mutually antagonise overall response and/or share a common metabolic pathway, thereby leading to adverse pharmacokinetic interactions. As more than two chemical entities are manufactured into a single dosage form, the chemical non-compatibility may reduce the shelf life of FDCs. Any FDC product which puts a patient at unnecessary health risk, and or whose benefits do not outweigh the risk, is usually termed as 'Irrational' [2, 4] .
Since 1961, FDCs have been proliferating -particularly in the past decde -and become highly popular on the Indian market. As of April 2018, the Central Drugs Standard Control Organization (CDSCO) had approved 1288 FDCs [6] . This number is disproportionately high compared to its counterpart in a tightly regulated market like USFDA, which has only a few hundred approved FDCs [7] . Even WHO's list of essential medicines mentions only 24 FDCs to meet most important needs in a health system [8] . Unfortunately, the majority of approved FDCs on the Indian market are irrational and lack scientific justification, as the scientific rigour of CDSCO in approving these FDCs has been questioned time and again in parliamentary and academic reports [9] [10] [11] . However, CDSCO has promulgated the policy guidelines for the approval of FDCs in 2013, and issued periodic bans on certain FDCs which are deemed irrational [12, 13] . Such bans are challenged by industry in the courts and currently subjudice. The Parliamentary standing committee on health and family welfare undertook a specialist task to investigate the current status of FDCs. Its 59th report in 2012 pointed out multiple deficiencies in the CDSCO's approval process of FDCs and highlighted institutional problems such as understaffing, lack of skills, and inadequate infrastructure on the part of CDSCO. However, the most significant observation concerned the issuance of manufacturing licenses by the State Licensing Authority (SLA) without the prior clearance of Drug Controller General of India DCG(I), the head of CDSCO. The report stated: 'Unfortunately some State Drug Authorities have issued manufacturing licenses for a very large number of FDCs without prior clearance from CDSCO. This is in violation of rules though till May 2002, there was some ambiguity on powers of the State Drug Authorities in this respect. However the end result is that many FDCs in the market have not been tested for efficacy and safety. This can put patients at risk.' [9] As per Drugs and Cosmetics act 1940, rule 122E, FDCs are considered as new drugs which have to be approved by CDSCO after due examination of the data on safety and efficacy [14] . The issuance of manufacturing licences by SLAs is subjected to such pre-approval from CDSCO. But SLAs have granted manufacturing licences to FDCs without prior clearance from CDSCO [9, 11] . Thus, the Indian pharmaceutical market is flooded with unapproved FDCs (1200 CDSCO approved vs. 6000 available), whose safety and efficacy was never tested and which are putting patients' lives at risk.
The choice of anti-infectives in general and anti-tubercular, antimalarial and antiretroviral drugs in particular was due to the prevalence of these diseases in tropical countries and because these medications have the highest number of rational FDCs approved all over the world. Drugs from these therapeutic categories can be combined in many ways, and some combinations may prove disastrous. Exposure to irrational FDCs of anti-infective drugs may contribute to drug resistance not only in India, but all over the world as many of these FDCs have been exported [15, 16] .
In this context, we aimed to generate a data on the proportion and sales of unapproved FDCs in India for anti-tubercular, antimalarial and antiretroviral medicines. The study is not about the scientific rationale of listed FDCs, but about highlighting the proportion of unapproved combinations and their market value.
Methods
The present study is an ecological study based on secondary data resources. Data were collected through AIOCD PharmaTrac, a market research database comprising monthly audits of pharmaceutical product sales. The database covers 23 regions of India through multiple supply channels consisting of 5000 pharmaceutical companies, 18 000 distributers and stockists, 32 000 sub-stockists and 500 000 retailers (including hospitals and dispensing doctors). The sample data are projected to reflect the overall sales in the country [17] . Our study aimed to analyse sales volumes, value and CDSCO approval status of FDC formulations in India. Data collection was limited to only three therapeutic categories: anti-tuberculosis, antimalarial and antiretroviral drugs.
In first phase, the approval status of all marketed FDCs in the selected categories was determined by comparing available FDCs with the ones approved by CDSCO [6] . In the second phase, we searched the AIOCD PharmaTrac database to determine the Moving Annual Total (MAT) in sales volume and value for the selected therapeutic categories. MAT data as of January 2018 were used, capturing the timeframe January to December 2017. Further evaluation of marketed FDCs in India against the drugs listed in National list of essential medicines (NLEM) was carried out [7] . The database was additionally searched using the individual and combination drug names in the selected therapeutic category. In the last phase, the international approval status of combinations from selected therapeutic categories was assessed, using 'Approved Drug Products with Therapeutic Equivalence Evaluations', commonly known as the Orange Book. This book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (USFDA) [7] .
Results

CDSCO approval status of marketed FDCs
Since 1961, CDSCO has approved 1288 FDCs (as of April 2018) as opposed to a few hundred approved by its US counterpart. A total of 32 combinations of first-to fourthline anti-tubercular therapy were approved by CDSCO, but 110 combinations were available, suggesting that approximately three-fourths of anti-tubercular FDCs on the market were unapproved ( Table 1 ). The market has 2477 branded products spinning out of 110 combinations, half of which were unapproved ( Table 2 ). The offset in the percentage after considering branded products in the case of antitubercular FDCs suggested a relatively lower tendency to prescribe unapproved products. Of 20 antimalarial FDCs available on the market, only eight were approved, pegging the percentage of unapproved products in this category to 60%. There were 494 antimalarial FDC products available, of which about half were unapproved (Table 3 ). In contrast, almost 95% of antiretroviral FDCs and branded products available on the market were approved (Table 4) .
Sales value and volume generated from unapproved FDCs in India
Sales value and volume data are the indicator of the consumption of unapproved FDCs in the market. The sales volume of all four line anti-tubercular therapy drugs was 730 million units, of which 71%, i.e. 522 million units were unapproved and amounting to 14.30 billion rupees in sales value (58%). Interestingly, after consideration of first line therapy anti-tubercular drugs, the percentage of sales value as well as volume rose considerably to 72% and 83% respectively.
Almost half of the sales value and volume of antimalarial drugs was generated from unapproved products, whereas unapproved antiretroviral FDCs generated only 1% of sales volume but 5% of sales value ( Figure 1 ).
CDSCO vs. NLEM comparison
The Indian List of Essential Medicines (NLEM) is developed by CDSCO in consultation with WHO. The list adheres to the basic principles of efficacy, safety and cost-effectiveness. Screening of the FDCs from the selected categories against NLEM reveals evasion of the Drug Price Control Order (DPCO) 2013 by pharmaceutical manufacturers [18] . Every individual drug formulated into the FDC from the given categories was screened against NLEM 2015, so that the data would reveal the number of FDCs which contain any one drug (at least) listed in the NLEM 2015. Surprisingly, there was only one FDC formulation each from anti-tubercular and antimalarial category which did not contain any drug listed (Tables 2 and 3 ). All other FDCs contain at least one drug which was listed in the NLEM 2015, while antiretroviral FDCs all contained at least one drug listed in the NLEM 2015 (Table 4 ). The Indian NLEM 2015 list only 24 FDC products, none of which interestingly is from the category of anti-tuberculars; but two FDCs from the antimalarial and nine from antiretroviral category are listed.
International status of FDCs marketed FDCs in India
Only two first-line anti-tubercular FDCs of 10 (20%), and three antimalarial FDCs of 21 (15%) marketed in India were available in US markets (Tables 2 and 3 ). The proportion rose to 41% for antiretroviral FDCs, i.e. seven of 17 marketed in India were approved by US FDA (Table 4) . This shows that large number of FDCs currently sold in India has never been approved overseas owing to safety and efficacy issues.
Discussion
This systematic study of anti-infectives in three therapeutic categories reveals the menace of unapproved FDCs in the Indian market. In two categories there are more unapproved FDCs than approved ones. These unapproved FDCs have given rise to hundreds of unapproved products, dosage forms and variants. Apart from the solid oral dosage forms, a sizable number constitute Intra Venous (IV route) formulations, especially antimalarials (Table 3) . Such unapproved formulations generate a sales volume of millions of units, and sales value on the order of billions of Indian Rupees (INR). These numbers confirm that the fears of unapproved FDCs in the Indian market are not unfounded. In fact, almost one in every two FDC formulations of anti-tubercular and antimalarial medicines available in India has never been tested for the safety and efficacy. Our study also provides credence to the concerns voiced in 59 th report about FDC regulations in India [9] . As our data do not take into account the approval status of each branded product, the true proportion of unapproved branded products could be much higher. The findings obtained for anti-infectives in this study are in line with those of McGettigan et al. [11] , who reported that 73% of NSAIDs and 81% of anti-depressants in India are unapproved. While the problem of unapproved FDC spans several categories, antiretrovirals and anti-diabetics fared better in such studies.
Tuberculosis (TB), malaria and HIV are deadly infectious diseases prevalent in the tropics [19, 20] . India has approximately 2.79 million estimated cases of TB, with mortality of 423 000 per year, the highest in the world. HIV and TB are comorbid conditions with 87 000 reported deaths per year [22] . For these infectious diseases, the social and economic impacts are devastating, including poverty, stigma and discrimination. Though the Indian Government has vowed to eradicate these diseases by 2025 in collaboration with WHO [23, 24] , these ambitions require concrete steps to achieve the goal. Despite treatment being available, there is evidence of treatment failure for these conditions, mainly due to the emergence of multidrug resistance into the parasites and/ or bacteria [25] [26] [27] . Along with poor patient compliance, the abuse or unwarranted use of anti-infectives has been demonstrated as a significant cause leading to the global threat of drug resistance [27] [28] [29] . The trends revealed in the study clearly show the abuse of the anti-infective therapy in India. There are 147 000 incidences per year of multidrug resistant (MDR) TB in the India alone [21] , where resistance has developed against first-line antitubercular therapy. Alarmingly, the percentage of unapproved first-line anti-tubercular FDCs in the Indian market stands at 70%.
As drug resistance has dramatically reduced the clinical efficacy of many antimalarial medicines, artemisinin combination therapy (ACT) has become a norm to treat complicated cases of malarial [30] [31] [32] [33] . Of six artemisinin-based FDCs available in India, three are unapproved jeopardising the prospective effectiveness of such therapies. There are more reasons to worry as the unwarranted use of such FDCs contributing to the drug resistance may not only be limited to India, since many irrational combinations are exported to the semi-or unregulated markets in Asia and Africa, compounding the drug resistance problem globally [16] . A large part of the reasoning of disproportionately high number of FDCs can be attributed to the approvals given by SLA without prior scrutiny by CDSCO. This overlap of functions or anomaly has been addressed in the 59th report, as it reasoned out that there is 'unexplained ambiguity' regarding the licensing powers of SLAs before the year 2002 which partially contributed to the problem [9] . However, current data show that a significant number of anti-infective FDCs with a launch date after 1 May 2002 still do not feature in the approval list of CDSCO. This is supported by the study conducted in 2015 by McGettigan et al. [11] , which showed similar trends about NSAIDS, and psychotropic drugs.
Careful scrutiny of the Drugs and Cosmetics Act and subsequent amendments thereof, leads us to believe that there is no evident ambiguity in the licensing authorities of CDSCO and SLA, as the licensing powers have always been with CDSCO. This opinion is seconded in the academic reports [11, 34, 35] .
Pharmaceutical manufacturers' intent to evade the Drugs Price Control Order (DPCO) can be considered as the second most important factor regarding irrational FDCs. As per DPCO (prior 2013), the drugs listed in the NLEM of India were under the purview of DPCO leading to a price cap, so price control was evaded by combining these drugs as a part of FDC [11, 36, 37] . Our data, which show that almost all FDCs have one of the drugs as a part of NLEM, confirm the validity of this argument. However, the Government has expanded the scope of DPCO by introducing the National Pharmaceutical Pricing Policy (NPPP)-2012, which has brought all the drugs listed in NLEM along with combination products having one of the drugs featured in NLEM under the ambit of price control. This is a welcome step, which has seemed to work so far as there are no new FDCs approved in the category of antimalarial, antiretroviral and first-line anti-TB categories since 2013, though there are very few FDCs in the anti-TB category (except firstline therapy) approved after 2013.
The Government of India with WHO has revised the National Tuberculosis Control Program (RNTCP) and National Vector Borne Disease Control Program (NVBDCP) to control TB and malaria, but the sales value and volume generated by unapproved anti-TB and antimalarial FDCs stands at more than 50%. This shows the lack of awareness and/or ignorance of the medical community on irrational FDCs and their possible implications in developing drug resistance for anti-infectives. Frequently, high sales turnover and prescription trends are projected to supplement the argument of their rationality by the medical community of India [36] . In the absence of strong pharmacovigilance network and data, it is difficult to prove conclusively the fallacy of this argument or otherwise. It has been reported that more than 50% of the prescriptions generated for anti-TB drugs are from private sector hospitals, and there is a large disparity between the treatment provided by private sector hospitals and RNTCP [38] . To make the treatment options for such infectious diseases uniformly rational, there is an urgent need to consolidate the treatments for infectious diseases on a single platform with common treatment options in line with national programmes (like RNTCP) which would enable to tackle the problem of irrational FDCs. Further, it is imperative to analyse the quality of FDCs along with the regulatory approval status, as the knowledge about the quality of FDCs is lacking. The majority of our estimates are on the quality of antimalarial medicines [39] , and very little is published on the quality of anti-tubercular and antiretroviral medicines.
The study has several limitations. First, it is based on secondary sources and the data sets are derived from publicly available records as well as a commercial database. These sources cannot be verified independently. Second, the PharmaTrac database captures 35% of the national sales and the sampling data are projected to estimate national sales total. Third, the sales data represent retailed inventory. It does not offset the sales value and volume from government-subsidised or free-of-cost drugs provided in government hospital pharmacies.
Conclusion
The large proportion of FDC formulations available in India have never been approved by CDSCO. About 70% of anti-tubercular and 60% of antimalarial FDC formulations are unapproved, generating more than 50% of their sales volume and value. The opaque regulatory framework and ambiguity over licensing power of SLAs and CDSCO have contributed to the problem. Although the government has shown the intent to tackle the issue by banning certain FDCs, the process has been questioned in a court of law. Thus, it is recommended that the government refrain from taking the parliamentary committee route, instead referring unapproved/irrational FDCs to DTAB to prevent any legal backlash. The rationality of unapproved FDCs should be reviewed and irrational formulations should be banned. To make informed decisions about the rationality of FDCs, post-marketing surveillance should be strengthened. The ambiguity/loophole in the regulatory framework must be plugged to prevent any such future approvals. Strong enforcement tools need to be brought to the disposal of regulatory agencies to take action against those manufacturing unapproved FDCs. Further, the medical community must be sensitised to the problem of unapproved FDCs, which pose a serious threat not only to India but also globally, as unabated use of such formulations may compound antibiotic resistance.
